Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients

Li, Xing; Zhong, Xiang; Chen, Zhan-Hong; Xing, Yan-Fang; Wu, Dong-Hao; Chen, Jie; Ma, Xiao-Kun; Lin, Qu; Wen, Jing-Yun; Wei, Li; Wang, Tian-Tian; Ruan, Dan-Yun; Lin, Ze-Xiao; Wu, Xiang-Yuan; Dong, Min

추천

검색

자료유형: 학술저널

저자정보: Li, Xing (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Zhong, Xiang (Shenzhen People's Hospital) Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Xing, Yan-Fang (Department of Nephrology, the Third Affiliated Hospital of Guangzhou Medical University) Wu, Dong-Hao (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Wang, Tian-Tian (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) Ruan, Dan-Yun (Department of Med) Lin, Ze-Xiao Wu, Xiang-Yuan Dong, Min

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제22호

발행연도: 2014.1

수록면: 9,635 - 9,641 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: This retrospective study was aimed to investigate the efficacy of prophylactic agents in hepatocellular carcinoma (HCC) patients receiving TACE and compare the difference between lamivudine and entecavir. Materials and Methods: A consecutive series of 203 HBV-related HCC patients receiving TACE were analyzed including 91 patients given prophylactic agents. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 IU/ml higher than the nadir level, hepatitis flares due to HBV reactivation and progression free survival (PFS) were the main endpoints. Results: Some 48 (69.6%) reached virologic response. Prophylaxis significantly reduced virologic events (8.8% vs 58.0%, p=0.000) and hepatitis flares (1.1% vs 13.4%, p=0.001). Patients presenting undetectable HBV DNA levels displayed a significantly improved PFS as compared to those who never achieved undetectable HBV DNA. Prophylaxis and e-antigen positivity were the only significant variables associated with virologic events. In addition, prophylaxis was the only independent protective factor for hepatitis flares. Liver cirrhosis, more cycles of TACE, HBV DNA negativity, a lower Cancer of the Liver Italian Program score, non-metastasis and no hepatitis flares were protective factors for PFS. Prophylactic lamivudine demonstrated similar efficacy as entecavir. Conclusions: Prophylactic agents are efficacious for prevention of HBV reactivation in HCC patients receiving TACE. Achievement of undetectable HBV DNA levels displayed a significant capability in improving PFS. Moreover, persistent tumor residual lesions, positive HBV DNA and hepatitis B flares might be causes of tumor progression in these patients.

#Hepatitis B virus #hepatocellular carcinoma #transcatheter arterial chemoembolization #prognostic analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요